Medical Affairs Inflammation & Early Pipeline, HP ROPU ASKAN

THE POSITION

Boehringer Ingelheim is strengthening its Inflammation Medical Affairs presence across the ASKAN region to provide regional scientific leadership for priority pipeline assets, from early medical strategy and ecosystem readiness through launch preparation.

The geographic influence of this role encompasses Australia, New Zealand, South Korea, Thailand, and Singapore, with primary strategic priority given to South Korea and Australia/New Zealand due to market size, scientific influence, and reimbursement complexity.

This is a high-impact pipeline leadership role with end-to-end accountability for the assigned asset portfolio across the region. The majority of the role’s initial focus will be dedicated to verducatib, however, as the Inflammation and early pipeline portfolio evolves, the position will assume regional Medical Affairs leadership for any new molecule progressing into launch preparation, ensuring continuity from early scientific engagement through market readiness, evidence generation, and medical governance.

Tasks & responsibilities

• Act as the single point of regional responsibility for all medical deliverables and scientific strategies related to the assigned Inflammation and early pipeline assets across ROPU ASKAN.
• Lead the overall medical strategy and tactical execution for the assigned portfolio, translating scientific and clinical insights into clear regional priorities, disease-area readiness, and plans to address significant unmet medical needs.
• Partner closely with local/countries medical teams, regional marketing, market access, and clinical operations to implement a cohesive, end-to-end Medical Affairs launch-readiness roadmap.
• Operate effectively within cross-functional teams: Commercial Operations, Regulatory Affairs, Market Access, Early Access Team, Clinical Development & Operations, Patient Safety & Pharmacovigilance, and Patient Engagement.
• Tailor strategic plans and resource allocation across South Korea, Australia, New Zealand, Thailand, and Singapore according to each market’s regulatory frameworks, HTA requirements, and healthcare system maturity.
• Plan, execute, and lead expert interaction platforms such as Advisory Boards, expert roundtables, consultancy groups, and market readiness panels to systematically capture critical clinical, diagnostic, access insights, and persistent unmet medical needs across all target markets.
• Build and maintain structured advocacy development plans with Key External Experts (pulmonologists, inflammatory disease specialists, CT chest radiologists) and relevant scientific societies.
• Represent BI’s scientific vision for the assigned Inflammation and early pipeline assets with excellence in communication, tailoring scientific exchange to KEEs and internal stakeholders.
• Represent BI’s scientific vision for the assigned Inflammation and early pipeline assets with excellence in communication, tailoring scientific exchange to KEEs and internal stakeholders.
• Design and execute regional medical education strategies, symposia, workshop sessions, train-the-trainer programs, and speaker tours to address key educational gaps related to disease burden, unmet medical needs, emerging science, and the clinical value of assigned pipeline assets.
• Develop and maintain deep scientific expertise in the assigned assets, their mechanisms of action, relevant disease biology, clinical development programs, and the evolving treatment landscape, remaining current on competitive dynamics and potential differentiation.
• Combine clinical insights with brand strategy to ensure all regional scientific initiatives address local unmet medical needs and support future market access.
• Lead regional evidence generation initiatives, including real-world evidence, epidemiological studies, registries, and clinical burden research, to characterize unmet medical needs and inform Health Technology Assessment and reimbursement submissions in priority markets.
• Collaborate with medical and market access teams to strengthen scientific understanding of relevant diagnostic approaches, patient identification, disease assessment, and care pathways for the assigned assets.
• Support Regional Clinical Operations with site selection, investigator engagement, feasibility assessments, and scientific input for global clinical development programs relevant to the assigned portfolio in ASKAN.
• Act as the primary regional medical point of contact for IIS and External Research Proposals, evaluating scientific merit and alignment with the regional strategy for the assigned portfolio.
• Drive omnichannel scientific engagement initiatives, leveraging digital platforms and virtual exchange tools tailored to HCP preferences across Australia, New Zealand, South Korea, Thailand, and Singapore.

Requirements

• Doctor of Medicine (MD), PharmD, or PhD in a relevant life sciences discipline.
• Minimum 5 years of Medical Affairs experience in a country-level role, and/or 2–3 years in a regional/multi-country role within the pharmaceutical industry.

• Experience or subspecialty background in Inflammation, Immunology, respiratory, or a relevant specialty area is a strong advantage, though not strictly required for candidates with proven scientific adaptability and the ability to rapidly build expertise across emerging pipeline assets.
• Experience in early access programs (compassionate use, etc.) is an advantage
• Demonstrated experience organizing Medical Affairs initiatives: Advisory Boards, Scientific Exchange Meetings, Speaker Forums, and structured KEE relationship management.
• Proven ability to navigate matrixed organizations and manage multi-country stakeholders across varying regulatory and cultural environments.
• Strong understanding of regional regulatory pathways and reimbursement frameworks (e.g., PBAC/TGA in Australia, HIRA/MFDS in South Korea).
• English fluency is required. Korean language proficiency is a significant advantage given the strategic weight and KEE engagement depth required for the South Korea market.
• Proficiency with Microsoft Office Suite (Word, Excel, PowerPoint) and digital omnichannel engagement tools (CRM platforms, virtual meeting technology).
• Preference may be given to candidates who do not require work visa sponsorship